NASDAQ · CVRX
Healthcare · Medical - Devices
$1.37
Down-$0.02 (-1.44%)
Updated Oct 22, 2026, 12:20 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CVRX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 21, 2026
CVRX closed at $1.37 after 21 trading sessions, down 49.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 21, 2026 | $1.38 | $1.38 | $1.30 | $1.37 | 282K |
| Oct 20, 2026 | $1.36 | $1.435 | $1.36 | $1.39 | 295.9K |
| Oct 19, 2026 | $1.30 | $1.36 | $1.275 | $1.35 | 357.99K |
| Oct 16, 2026 | $1.39 | $1.39 | $1.255 | $1.30 | 382.72K |
| Oct 15, 2026 | $1.36 | $1.44 | $1.332 | $1.39 | 361.67K |
| Oct 14, 2026 | $1.33 | $1.40 | $1.28 | $1.34 | 893.43K |
| Oct 13, 2026 | $1.49 | $1.49 | $1.35 | $1.36 | 490.5K |
| Oct 12, 2026 | $1.58 | $1.665 | $1.465 | $1.48 | 470.17K |
| Oct 9, 2026 | $1.66 | $1.68 | $1.56 | $1.58 | 398.66K |
| Oct 8, 2026 | $1.64 | $1.68 | $1.55 | $1.68 | 520.41K |
| Oct 7, 2026 | $1.62 | $1.76 | $1.62 | $1.67 | 896.58K |
| Oct 6, 2026 | $1.54 | $1.69 | $1.54 | $1.62 | 537.13K |
| Oct 5, 2026 | $1.57 | $1.62 | $1.505 | $1.56 | 577.78K |
| Oct 2, 2026 | $1.58 | $1.665 | $1.51 | $1.55 | 1.06M |
| Oct 1, 2026 | $1.745 | $1.79 | $1.50 | $1.53 | 1.46M |
| Sep 30, 2026 | $2.63 | $2.65 | $1.65 | $1.75 | 4.27M |
| Sep 29, 2026 | $2.60 | $2.755 | $2.53 | $2.63 | 373.4K |
| Sep 28, 2026 | $2.69 | $2.79 | $2.53 | $2.59 | 381.98K |
| Sep 25, 2026 | $2.56 | $2.70 | $2.51 | $2.70 | 462.36K |
| Sep 24, 2026 | $2.73 | $2.73 | $2.51 | $2.53 | 693.69K |
| Sep 23, 2026 | $2.89 | $2.89 | $2.70 | $2.72 | 482.04K |
The latest Smart Investors Daily articles mentioning CVRX.
Company
Market Activity
Research & News
CVRX research
Company profile and research snapshot.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 7, 2026 | Lake Street | Hold | — |
| Apr 14, 2026 | Canaccord Genuity | Buy | — |
| Feb 13, 2026 | Canaccord Genuity | Buy | — |
| Nov 6, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 12, 2026
On Thursday, CVRx (NASDAQ:CVRX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and
Yahoo · Sep 29, 2026
MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will be held Oct. 9-12, 2026, in Phoenix. Barostim will be featured across eight events at HFSA,
Benzinga · Sep 29, 2026
CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of
Benzinga · Sep 21, 2026
CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CVRX.
